

WEST Search History

DATE: Wednesday, July 23, 2003

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
-----------------	--------------	------------------	-----------------

side by side

result set

DB=USPT; PLUR=YES; OP=ADJ

L6	L5 and hepatitis c	36	L6
----	--------------------	----	----

L5	L4 and treat\$4	60	L5
----	-----------------	----	----

L4	L3 and hepatitis	60	L4
----	------------------	----	----

L3	L2 and interferon	91	L3
----	-------------------	----	----

L2	L1 and ribavirin	119	L2
----	------------------	-----	----

L1	((424/85.7 424/85.4)!.CCLS. (530/351)!.CCLS. (514/2 514/21 514/43 514/894)!.CCLS.)	7470	L1
----	--	------	----

END OF SEARCH HISTORY

(FILE 'HOME' ENTERED AT 14:51:30 ON 23 JUL 2003)

FILE 'CAPLUS, MEDLINE, USPATFULL' ENTERED AT 14:52:00 ON 23 JUL 2003

L1 6361 S RIBAVIRIN
L2 2106 S L1 AND (INTERFERON ALFA OR INTERFERON ALPHA)
L3 1639 S L2 AND (HEPATITIS C OR HCV)

FILE 'REGISTRY' ENTERED AT 14:55:16 ON 23 JUL 2003

L4 STRUCTURE UPLOADED
L5 1 S L4 SSS SAM
L6 2 S L4 SSS FULL

FILE 'CAPLUS, MEDLINE, USPATFULL' ENTERED AT 14:59:18 ON 23 JUL 2003

L7 8 S L3 AND L6

=>

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003004119	A1	20030102	US 2001-837609	20010418
PRIORITY APPLN. INFO.:			US 2001-837609	20010418
OTHER SOURCE(S):	MARPAT 138:49905			
IT	264621-14-9P			
	RL: SPN (Synthetic preparation); PREP (Preparation)			
	(ribavirin-interferon-.alpha. combination			
	therapy for eradicating detectable HCV-RNA in patients havin			
	chronic hepatitis C infection)			
RN	264621-14-9 CAPLUS			
CN	1H-1,2,4-Triazole-3-carboxamide, 1-[5-O-(2-methylbenzoyl)-.beta			
	ribofuranosyl]- (9CI) (CA INDEX NAME)			

Chemical structure of a nucleoside derivative. The structure shows a benzoyl group (a benzene ring with a methyl group at the 3-position and a carbonyl group at the 1-position) attached via an ester linkage to the 5' carbon of a ribose sugar. The sugar has hydroxyl groups at the 2' and 3' positions. The 1' carbon is attached to a purine base, which has an amide group (-CONH₂) at the 6-position. Stereochemistry is indicated with wedges and dashes.

L7 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2002 ACS on STN
ACCESSION NUMBER: 2002:444490 CAPLUS
DOCUMENT NUMBER: 137:15760
TITLE: **Ribavirin derivative-interferon-
alpha.** combination therapy for eradicating
detectable **HCV**-RNA in patients having
chronic **hepatitis C** infection, and
preparation of **ribavirin** derivatives
INVENTOR(S): Ganguly, Ashit K.; McCormick, Jinping; Lovey, Raymond
G.; Bennett, Frank; Saksena, Anil K.; Girijavallabhan,
Viyyoor M.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: U.S., 41 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6403564	B1	20020611	US 1999-417884	19991014
PRIORITY APPLN. INFO.:			US 1998-104566P	P 19981016
			US 1999-142854P	P 19990707

OTHER SOURCE(S): MARPAT 137:15760

IT **264621-14-9P**


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(**ribavirin** deriv.-**interferon**-.**alpha**. combination therapy for eradicating detectable **HCV**-RNA in patients with chronic **hepatitis C** infection, and prepn. of **ribavirin** derivs.)

RN 264621-14-9 CAPLUS

CN 1H-1,2,4-Triazole-3-carboxamide, 1-[5-O-(2-methylbenzoyl)-.beta.-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:798236 CAPLUS

DOCUMENT NUMBER: 135:339213

TITLE: **Ribavirin-interferon alfa**
combination therapy for eradicating detectable **HCV**-RNA in patients having chronic **hepatitis C** infection

INVENTOR(S): Ganguly, Ashit K.; McCormick, Jinping; Lovey, Raymond G.; Bennett, Frank; Saksena, Anil K.; Girijavallabhan, Viyyoor M.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 104 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001081359	A1	20011101	WO 2001-US12760	20010418
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002055473	A1	20020509	US 2001-837491	20010418

EP 1282632 A1 20030212 EP 2001-928662 20010418
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 PRIORITY APPLN. INFO.: US 2000-198801P P 20000420
 WO 2001-US12760 W 20010418


IT 264621-14-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of **ribavirin** derivs. and combination therapy with
interferon-.alpha. for eradicating detectable
HCV-RNA in patients having chronic **hepatitis**
C infection)

RN 264621-14-9 CAPLUS

CN 1H-1,2,4-Triazole-3-carboxamide, 1-[5-O-(2-methylbenzoyl)-.beta.-D-
 ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2000:277992 CAPLUS

DOCUMENT NUMBER: 132:293978

TITLE: Preparation of **Ribavirin** derivs. and use in
interferon alfa combination therapy
 for eradicating detectable **HCV-RNA** in
 patients having chronic **hepatitis C**
 infection

INVENTOR(S): Ganguly, Ashit K.; McCormick, Jinping; Lovey, Raymond
 G.; Bennett, Frank; Saksena, Anil K.; Girijavallabhan,
 Viyyoor M.

PATENT ASSIGNEE(S): Schering Corp., USA

SOURCE: PCT Int. Appl., 93 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000023455	A1	20000427	WO 1999-US21450	19991014
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1121370	A1	20010808	EP 1999-970663	19991014
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			

PRIORITY APPLN. INFO.: US 1998-174059 A2 19981016

WO 1999-US21450 W 19991014

OTHER SOURCE(S): MARPAT 132:293978

IT 264621-14-9P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of **ribavirin** derivs. and use in chronic **hepatitis C** infection)

RN 264621-14-9 CAPLUS

CN 1H-1,2,4-Triazole-3-carboxamide, 1-[5-O-(2-methylbenzoyl)-.beta.-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2000:277991 CAPLUS

DOCUMENT NUMBER: 132:293977

TITLE: Preparation of **Ribavirin** derivs. and use in **interferon alfa** combination therapy for eradicating detectable **HCV**-RNA in patients having chronic **hepatitis C** infection

INVENTOR(S): Ganguly, Ashit K.; McCormick, Jinpinging; Lovey, Raymond G.; Bennett, Frank; Saksena, Anil K.; Girijavallabhan, Viyyoor M.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 123 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000023454	A1	20000427	WO 1999-US21448	19991014
W:				
AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:				
GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6277830	B1	20010821	US 1999-348534	19990707
CA 2346447	AA	20000427	CA 1999-2346447	19991014
EP 1121369	A1	20010808	EP 1999-970662	19991014
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9915546	A	20010814	BR 1999-15546	19991014
JP 2002527522	T2	20020827	JP 2000-577180	19991014
NO 2001001789	A	20010611	NO 2001-1789	20010409

PRIORITY APPLN. INFO.: US 1998-174059 A 19981016
US 1999-348534 A 19990707
WO 1999-US21448 W 19991014

OTHER SOURCE(S): MARPAT 132:293977


IT 264621-14-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of **Ribavirin** derivs. and use in chronic **hepatitis C** infection)

RN 264621-14-9 CAPLUS

CN 1H-1,2,4-Triazole-3-carboxamide, 1-[5-O-(2-methylbenzoyl)-.beta.-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2003:4080 USPATFULL

TITLE: **Ribavirin-interferon alfa**
combination therapy for eradicating detectable
HCV-RNA in patients having chronic
hepatitis C infection

INVENTOR(S): Ganguly, Ashit K., Upper Montclair, NJ, UNITED STATES
McCormick, Jinping, Edison, NJ, UNITED STATES
Lovey, Raymond G., West Caldwell, NJ, UNITED STATES
Bennett, Frank, Piscataway, NJ, UNITED STATES
Saksena, Anil K., Upper Montclair, NJ, UNITED STATES
Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003004119	A1	20030102
APPLICATION INFO.:	US 2001-837609	A1	20010418 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530		
NUMBER OF CLAIMS:	40		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1785		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 264621-14-9P

(ribavirin-interferon-.alpha. combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection)

RN 264621-14-9 USPATFULL

CN 1H-1,2,4-Triazole-3-carboxamide, 1-[5-O-(2-methylbenzoyl)-.beta.-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 7 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2002:136974 USPATFULL

TITLE: **Ribavirin-interferon alfa**
combination therapy for eradicating detectable
HCV-RNA in patients having chronic
hepatitis C infection

INVENTOR(S): Ganguly, Ashit K., Upper Montclair, NJ, United States
McCormick, Jinping, Edison, NJ, United States
Lovey, Raymond G., West Caldwell, NJ, United States
Bennett, Frank, Piscataway, NJ, United States
Saksena, Anil K., Upper Montclair, NJ, United States
Girijavallabhan, Viyyoor M., Parsippany, NJ, United States

PATENT ASSIGNEE(S): Schering Corporation, Kenilworth, NJ, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6403564	B1	20020611
APPLICATION INFO.:	US 1999-417884		19991014 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-142854P	19990707 (60)
	US 1998-104566P	19981016 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Low, Christopher S. F.	
ASSISTANT EXAMINER:	Mohamed, Abdel A.	
LEGAL REPRESENTATIVE:	Hoffman, Thomas D.	
NUMBER OF CLAIMS:	2	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	1601	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT **264621-14-9P**

(ribavirin deriv.-interferon-.alpha. combination therapy for
eradicating detectable HCV-RNA in patients with chronic hepatitis C
infection, and prepn. of ribavirin derivs.)

RN 264621-14-9 USPATFULL

CN 1H-1,2,4-Triazole-3-carboxamide, 1-[5-O-(2-methylbenzoyl)-.beta.-D-
ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 8 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2002:106264 USPATFULL

TITLE: **Ribavirin-interferon alfa**
combination therapy for eradicating detectable
HCV-RNA in patients having chronic
hepatitis C infection

INVENTOR(S): Ganguly, Ashit K., Upper Montclair, NJ, UNITED STATES
McCormick, Jinping, Edison, NJ, UNITED STATES
Lovey, Raymond G., West Caldwell, NJ, UNITED STATES
Bennett, Frank, Piscataway, NJ, UNITED STATES
Saksena, Anil K., Upper Montclair, NJ, UNITED STATES
Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002055473	A1	20020509
APPLICATION INFO.:	US 2001-837491	A1	20010418 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-198801P	20000420 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1870	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

IT **264621-14-9P**

(prepn. of ribavirin derivs. and combination therapy with
interferon-.alpha. for eradicating detectable HCV-RNA in patients
having chronic hepatitis C infection)

RN 264621-14-9 USPATFULL

CN 1H-1,2,4-Triazole-3-carboxamide, 1-[5-O-(2-methylbenzoyl)-.beta.-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

